01:12 , Feb 2, 2018 |  BC Innovations  |  Translation in Brief

Untangling MS

Multiple sclerosis researchers have typically sought to dial down inflammation and reduce disease metrics that encompass a wide range of disabilities. A UCLA team is bucking those trends by identifying disease-modifying targets in specific brain...
16:47 , Feb 1, 2018 |  BC Innovations  |  Distillery Therapeutics

Autoimmune disease

INDICATION: Multiple sclerosis (MS) Patient sample and mouse studies suggest agonizing ABCA1 could help treat MS. In the experimental autoimmune encephalomyelitis (EAE) mouse model of MS, a tool compound ABCA1 agonist increased walking ability and...
13:21 , May 31, 2017 |  BC Innovations  |  Distillery Techniques

Disease models

TECHNOLOGY: 3-D models Mouse intestinal organoids could be used to model intestinal drug metabolism and toxicity. The organoids were generated by treating primary mouse crypt cells isolated from the small intestine with a cocktail of...
00:53 , Dec 31, 2016 |  BioCentury  |  Finance

Delivering takeouts

  BioCentury’s 25th annual Buyside View finds biotech investors focusing on mid-cap names with late-stage or marketed products that could become M&A targets. “The main theme playing at the moment is investors like us are...
07:00 , Jul 27, 2015 |  BC Week In Review  |  Clinical News

MDCO-216: Phase I data

A double-blind, placebo-controlled Phase I trial in 24 healthy volunteers and 24 patients with coronary artery disease (CAD) showed that single doses of 5-40 mg/kg IV MDCO-216 were well tolerated with no serious events or...
00:50 , Mar 27, 2015 |  BC Extra  |  Financial News

Cerenis raises EUR 53.4M in Euronext IPO

Cardiovascular play Cerenis Therapeutics S.A. (Euronext:CEREN) raised EUR 53.4 million ($57.7 million) through the sale of 4.2 million shares at EUR 12.70 in an IPO on Euronext. The IPO price values Cerenis at EUR 225.9...
07:00 , Sep 15, 2014 |  BC Week In Review  |  Clinical News

Cerenis HDL regulatory update

Cerenis said the European Commission granted Orphan Drug designation to CER-001 to treat apolipoprotein A-1 (APOA1) and ATP-binding cassette transporter 1 ( ABCA1 ) deficiencies. The company said inherited defects in the APOA1 or ABCA1...
07:00 , Oct 10, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine/metabolic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Hypercholesterolemia; hyperlipidemia ATP-binding cassette sub-family A member 1 (ABCA1); microsomal triglyceride transfer protein (MTTP; MTP) Mouse studies suggest inhibiting MTP and ABCA1 in the...
07:00 , Apr 18, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Ophthalmic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Ophthalmic disease Age-related macular degeneration (AMD) ATP-binding cassette sub-family A member 1 (ABCA1); liver X receptor (LXR); microRNA-33 (miR-33) In vitro and mouse studies suggest increasing...
07:00 , Sep 12, 2011 |  BioCentury  |  Product Development

Reviving CETP

Evidence is accumulating that the next generation of CETP inhibitors may be able to avoid the off-target effects that doomed Pfizer Inc. 's torcetrapib. Roche reported Phase IIb data in late August showing its dalcetrapib...